论文信息 - A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. - 字舞流文

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma.

M. Mehdorn | M. Westphal | G. Schackert | U. Schlegel | J. Steinbach | T. Pietsch | K. Geletneky | C. Senft | O. Schnell | M. Simon | D. Reuter | O. Heese | Christian Braun | F. Bach | D. Schulz | Joachim G Hartung | Monika Warmuth Metz | M. Simon | M. Simon